

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/593 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61P A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE C. DOCUMENTS CONSIDERED TO BE RELEVANT Category 9 Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X,P TENG M ET AL: "Survival benefit of 1 - 18Zemplar compared with Calcijex among dialysis patients" JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. vol. 13, no. Program and Abstracts Issue, September 2002 (2002-09), page 461A XP009021255 Meeting of the American Society of Nephrology; Philadelphia, PA, USA; October 30-November 04, 2002 ISSN: 1046-6673 the whole document -/--| X | Further documents are listed in the continuation of box C. Patent family members are listed in annex. X Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the least terms. "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. O document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the International search report 17 November 2003 02/12/2003 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3018 Loher, F

Form PCT/ISA/210 (second sheet) (July 1992)



Internation Application No
PCT/US 03/25780

0.40	ALL DOGUMENTO CONGRESSES TO DE COLORDO	FC1/U3 U3/25/80
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category	Citation of document, with indication, where appropriate, or the relevant passages	Helevant to claim No.
X .	MARCO M P ET AL: "Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients" AMERICAN JOURNAL OF KIDNEY DISEASES 2001 UNITED STATES, vol. 38, no. 5, 2001, pages 965-974, XP009021253 ISSN: 0272-6386 page 971, left-hand column, line 34 - line 42	1-18
X	US 4 391 802 A (SUDA TATSUO ET AL) 5 July 1983 (1983-07-05) example 1	1-18
X	DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1996 (1996-12) SZELACHOWSKA M ET AL: "'Idiopathic Fanconi syndrome in an adult!" Database accession no. NLM9273236 XP002261654 abstract & POLSKI MERKURIUSZ LEKARSKI: ORGAN POLSKIEGO TOWARZYSTWA LEKARSKIEGO. POLAND DEC 1996, vol. 1, no. 6, December 1996 (1996-12), pages 414-416, ISSN: 1426-9686	1-18
X	TARANTINO G ET AL: "The efficacy of oral and intravenous calcitriol pulses therapy in hemodialysis patients: Four years follow-up" NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 16, no. 6, June 2001 (2001-06), page A130 XP002261653 Annual Congress of the European Renal Association and the European Dialysis and Transplant Associati; Vienna, Austria; June 24-27, 2001 ISSN: 0931-0509 the whole document	1,3-12, 14-18
X	LLACH F: "Paricalcito1: An updated review and guidelines for use" DIALYSIS AND TRANSPLANTATION 2001 UNITED STATES, vol. 30, no. 10, 2001, pages 654-664, XP009021122 ISSN: 0090-2934 see especially "conclusions" page 662, right-hand column -/	1,2, 4-13, 15-18



Internation Application No
PCT/US 03/25780

C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	FC1/03 03/23/60
Category °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BERWECK S ET AL: "Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia" CLINICAL NEPHROLOGY 2000 GERMANY, vol. 53, no. SUPPL. 1, 2000, pages S80-S85, XP009021123 ISSN: 0301-0430 First sentence page S80, right-hand column page S83, last paragraph -page S84, paragraph 1	1,3-12, 15-18
X	MARTIN K J ET AL: "PARICALCITOL DOSING ACCORDING TO BODY WEIGHT OR SEVERITY OF HYPERPARATHYROIDISM: A DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY" AMERICAN JOURNAL OF KIDNEY DISEASES, W.B. SAUNDERS, PHILADELPPHIA, PA, US, vol. 38, no. 5, SUPPL 5, November 2001 (2001-11), pages S57-S63, XP009005498 ISSN: 0272-6386 page S62, last paragraph -page S63, paragraph 1	1,2, 4-13, 15-18
X	CADA D J ET AL: "PARICALCITOL INJECTION AND RIBAVIRIN/INTERFERON ALFA-2B" HOSPITAL PHARMACY, LIPPINCOTT, PHILADELPHIA, US, vol. 34, no. 3, March 1999 (1999-03), pages 303-305,309-310,315-316,319-320,322-323-,3 35-338, XP009005495 ISSN: 0018-5787 page 303 -page 310	1,2, 4-13, 15-18
X	LINDBERG J ET AL: "A LONG-TERM, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PARICALCITOL IN END-STAGE RENAL DISEASE" CLINICAL NEPHROLOGY, DUSTRI VERLAG, NUENCHEN-DEISENHOFEN, DE, vol. 56, no. 4, October 2001 (2001-10), pages 315-323, XP009005488 ISSN: 0301-0430 page 316, left-hand column, line 8 - line 14 page 322, left-hand column, paragraph 2 table 3	1,2,4-9



1	Internation polication No	
	PCT/US 03/25780	

ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
TENG MING ET AL: "Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy." THE NEW ENGLAND JOURNAL OF MEDICINE. UNITED STATES 31 JUL 2003, vol. 349, no. 5, 31 July 2003 (2003-07-31), pages 446-456, XP009021112 ISSN: 1533-4406 cited in the application the whole document	1-18
DRÜEKE TILMAN B ET AL: "Paricalcitol as compared with calcitriol in patients undergoing hemodialysis." THE NEW ENGLAND JOURNAL OF MEDICINE. UNITED STATES 31 JUL 2003, vol. 349, no. 5, 31 July 2003 (2003-07-31), pages 496-499, XP009021120 ISSN: 1533-4406 the whole document	1-18
;	
	TENG MING ET AL: "Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy." THE NEW ENGLAND JOURNAL OF MEDICINE. UNITED STATES 31 JUL 2003, vol. 349, no. 5, 31 July 2003 (2003-07-31), pages 446-456, XP009021112 ISSN: 1533-4406 cited in the application the whole document DRÜEKE TILMAN B ET AL: "Paricalcitol as compared with calcitriol in patients undergoing hemodialysis." THE NEW ENGLAND JOURNAL OF MEDICINE. UNITED STATES 31 JUL 2003, vol. 349, no. 5, 31 July 2003 (2003-07-31), pages 496-499, XP009021120 ISSN: 1533-4406



International application No. PCT/US 03/25780

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210
2.	Claims Nos.: because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
з	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This inte	emational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 6--18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy



Internacion	pplication No
PCT/US	03/25780

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4391802	A	05-07-1983	JP	1015484 B	17-03-1989
			JP	1529805 C	15-11-1989
			JP	57149224 A	14-09-1982